After slipping to session lows, equities have remained near those levels. The S&P 500 is off by 0.1%.
Energy stocks trail behind the broader market as crude oil is sliding nearly 1.5%. Haliburton (HAL 33.50, -0.57) is lower by 1.7% while Schlumberger Limited (SLB 73.23, -0.87) and EOG Resources (EOG 107.77, -1.05) are down near 1.0%. Meanwhile, GreenHunter Energy (GRH 2.25, +0.09) is up 4.2% after eliminating all outstanding convertible preferred shares.
FRCN – Trade Alert
Up 80.85% in morning trading to $.0085 with 6M shares traded
Firemans Contractors, Inc. is a full-service contractor providing professional services for commercial and government clients, offering Business to Business Franchise Opportunities. Its services include Road Improvements, Pavement Maintenance, Seal Coating, Parking Lot Striping, Pavement Marking, Asphalt Maintenance and Repair, and ADA Compliance. Firemans Contractors has completed its FDD requirements with the Federal Trade Commission and has developed franchise territories across the U.S. The company’s goal is to develop hundreds of new franchise locations in the next 24 to 48 months. Firemans Contractors, Inc. (FRCN) announced this week that the company benefited from a total combined repeat business of 36% and 61% in 2010 and 2011, respectively, with the stimulus seeming to stem from continuous additions of Fortune 500 companies and large property management companies to the client portfolio.
To Read Full Story go to: http://www.pennytrader.com/quotes/FRCN.php
PRTN – News Alert
Up 9% in morning trading to $.42 with 6M shares traded
Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, pari-menopausal, and post-menopausal women. Eaton Scientific Systems, Ltd. , a wholly owned subsidiary of Pristine Solutions, Inc. (PRTN) announced select details of its planned multi-phase multi-location clinic trials for FDA approval of its novel drug indication Tropine 3, containing currently FDA approved Homatropine, in oral an suspension.
To Read Full Story go to: http://www.pennytrader.com/quotes/PRTN.php
STVF – News Alert
Up 11.11% in morning trading to $.30 with 100K shares traded
Stevia First Corp. is seeking to establish a vertically-integrated stevia enterprise in the U.S. with expertise in stevia seed and tissue propagation, plant breeding, and cultivation. Stevia First’s U.S. operations are located in the heart of California’s Central Valley, one of the world’s most productive agricultural regions. Stevia First Corp. (STVF) announced that the Company has entered into an exclusive and worldwide intellectual property license with the Vineland Research and Innovation Centre (”Vineland”) of Ontario, Canada.
To Read Full Story go to: http://www.pennytrader.com/quotes/STVF.php
To Follow PennyTrader on Twitter: http://twitter.com/pennytrader
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on PennyTrader.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.